Guangdong-Macao Pharmaceutical Co., Ltd. (hereinafter referred to as “the company”) is a wholly-owned subsidiary of GMTCM Park. The company was established in May 2016 with a registered capital of 250 million yuan and an aggregate investment of 550 million yuan. It is mainly responsible for the operation and management of the drug production service platform. Covering an area of about 15,000 square meters with a total construction area of about 35,000 square meters, the company was invested in and constructed in accordance with the GMP standards of China and the EU, and it has a complete production and quality management system. The Phase I project has built a quality testing platform and three workshops for the extraction of TCM (pretreatment) and production of oral solid preparations and liniments, including five production lines for tablets, capsules, granules, pills and liniments. The workshops adopt intelligent control systems and are equipped with world-class pharmaceutical equipment from Germany, Italy and the United States. In the future, the company will strive to build itself into an international and comprehensive service platform, integrating R&D, testing, pilot scale production, registration, and quality evaluation of TCM and related products.

• 2016 year

  established time

• 250 million

  registered fund

• 550 million

  invest amount

• 35 thousand

  construction area